SMARCB1 299 (INI1)-negative rhabdoid carcinomas of the gastrointestinal 300 tract: Clinicopathologic and molecular study of a highly ag-301 gressive variant with literature review, Am J Surg Pathol, vol.38, issue.7, pp.910-920, 2014. ,
, , p.304
Pancreatic undifferentiated rhabdoid car-305 cinoma: KRAS alterations and SMARCB1 expression status 306 define two subtypes, Mod Pathol, vol.28, issue.2, 2015. ,
SMARCA4-deficient sinonasal 308 carcinoma, Head Neck Pathol, vol.11, issue.4, 2017. ,
, , p.310
Prognostic value of KRAS mutations in stage 311 III colon cancer: Post hoc analysis of the PETACC8 phase III 312 trial dataset, Ann Oncol, vol.25, issue.12, 2014. ,
, , p.314
Frequent hSNF5/INI1 germline mutations in pa-315 tients with rhabdoid tumor, Clin Cancer Res, vol.17, issue.1, pp.316-347, 2011. ,
Extracranial rhabdoid 318 tumours: What we have learned so far and future directions, p.319 ,
, Lancet Oncol, vol.14, issue.8, pp.329-336, 2013.
, , p.321
Balanced translocations disrupting 322 SMARCB1 are hallmark recurrent genetic alterations in renal 323 medullary carcinomas, Eur Urol, vol.69, issue.6, pp.1055-1061, 2016. ,
, , p.325
SMARCB1-326 deficient vulvar neoplasms: A clinicopathologic, immunohis-327 tochemical, and molecular genetic study of 14 cases, Am J, p.328 ,
, Surg Pathol, vol.39, issue.6, pp.836-849, 2015.
,
SMARCB1/INI1 protein expression in round cell 331 soft tissue sarcomas associated with chromosomal transloca-332 EWS: A special reference to SMARCB1/INI1 333 negative variant extraskeletal myxoid chondrosarcoma, Am J, p.334 ,
, Surg Pathol, vol.32, issue.8, pp.1168-1174, 2008.
Bour-336 deaut and O. Delattre, SWI/SNF chromatin remodeling and 337 human malignancies, Annu Rev Pathol, vol.10, pp.145-171, 2015. ,
, , p.339
The chromatin remodelling component ,
, SMARCB1/INI1 influences the metastatic behavior of col-341 orectal cancer through a gene signature mapping to chromo-342 some 22, J Transl Med, vol.11, p.297, 2013.
, , p.344
A novel case of rhabdoid colon carcinoma 345 associated with a positive CpG island methylator phenotype 346 and BRAF mutation, Hum Pathol, vol.42, issue.7, pp.1047-1052, 2011. ,
,
Oxaliplatin, fluorouracil, and leucovorin 349 with or without cetuximab in patients with resected stage III 350 colon cancer (PETACC-8): An open-label, randomised phase 351 3 trial, Lancet Oncol, vol.15, issue.8, pp.862-873, 2014. ,
,
Prognostic effect of BRAF and KRAS muta-354 tions in patients with stage III colon cancer treated with leu-355 covorin, fluorouracil, and oxaliplatin with or without cetux-356 imab: A post hoc analysis of the PETACC-8 trial, JAMA On-357 col, pp.1-11, 2016. ,
, , p.359
Prognostic value of BRAF and KRAS mu-360 tations in MSI and MSS stage III colon cancer, J Natl Cancer, vol.361, issue.5, 2017. ,
, , p.363
Deep intronic hotspot 364 variant explaining rhabdoid tumor predisposition syndrome in 365 two patients with atypical teratoid and rhabdoid tumor, Eur J 366 Hum Genet, vol.25, issue.10, pp.1170-1172, 2017. ,
An-368 drás et al, Primary rhabdoid cancer of the ileum: A case report 369 and review of the literature, Pathol Res Pract, vol.206, issue.2, pp.110-115, 2010. ,
Molecular path-372 ways: SWI/SNF (BAF) complexes are frequently mutated in 373 cancer-mechanisms and potential therapeutic insights, Cancer Res, vol.374, issue.1, pp.21-27, 2014. ,
Loss of INI1 expression in colorectal carci-377 noma is associated with high tumor grade, poor survival, 378 BRAFV600E mutation, and mismatch repair deficiency, Hum, vol.379, pp.83-90, 2016. ,
Molecular path-381 ways: SWI/SNF (BAF) complexes are frequently mutated in 382 cancer-mechanisms and potential therapeutic insights, Cancer Res, vol.383, issue.1, pp.21-27, 2014. ,
, Z, p.385
Fibroblast growth factor receptors as novel ther-386 apeutic targets in SNF5-deleted malignant rhabdoid tumors, p.387 ,
, PloS One, vol.8, issue.10, p.77652, 2013.